Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 14 best booming stocks to buy right now. On January 8, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on the stock with a share price target of $56. Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) This update is a reaffirmation of the firm’s revision on the stock on December 9, when it lifted the price target to $56 from $35 after the company shared encouraging data from the Phase 1 study of TERN-701, ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Terns has had a successful year in 2025 and anticipates continued excitement in 2026, with the potential to become a best-in-disease therapy in the CML market [3] - The company has demonstrated unprecedented efficacy along with a strong safety and tolerability profile, positioning itself for the next generation of CML therapies [3] - Terns plans to engage with the FDA to discuss trial design and aims to initiate second-line and first-line trials promptly [4] Financial Position - Terns currently holds $1 billion in cash on its balance sheet, providing a strong financial foundation for upcoming trials and initiatives [4]

Summary of Terns Pharmaceuticals FY Conference Call Company Overview - **Company**: Terns Pharmaceuticals (NasdaqGS:TERN) - **Event**: FY Conference Call on January 12, 2026 - **Key Speakers**: Amy Burroughs (CEO), Emil Kuriakose (CMO), Scott Harris (CDO) [1] Industry Context - **Industry**: Chronic Myeloid Leukemia (CML) treatment - **Current Market Dynamics**: - CML was previously a fatal disease until the introduction of BCR-ABL inhibitors like Gleevec (Imatinib) in 2001 - Asiminib, an allosteric inhibitor, gained a 22% market share in the front-line treatment within three quarters of its approval in November 2024 [4][5] Core Points and Arguments - **Performance in 2025**: Terns had a successful year and anticipates continued success in 2026, aiming to establish itself as a leader in CML therapy [2] - **Financial Position**: Terns has $1 billion in cash, alleviating financing concerns until commercial launch [3] - **Efficacy of Terns 701**: - Terns 701 shows unprecedented efficacy with a 75% major molecular response (MMR) rate in a highly refractory patient population [6][9] - Deep molecular response (DMR) rate of 36% at recommended doses [7] - Comparison with Asiminib indicates Terns 701 may outperform in both efficacy and safety [10][20] - **Safety Profile**: - No dose-limiting toxicities observed; majority of adverse events were low-grade [9][11] - Terns 701 does not exhibit the pancreatic toxicity (20%) or hypertension (18%) seen with Asiminib [5][6] - Administered once daily without food restrictions, enhancing patient convenience [9][26] Market Opportunities - **Potential for Terns 701**: - Positioned as a next-generation therapy with better efficacy and safety compared to existing treatments [10][25] - Anticipated to capture significant market share in the front-line treatment of CML [25][26] - **Regulatory Pathway**: - Plans to engage with the FDA for trial design and dose selection in 2026 [22][29] - A second-line plus trial is expected to be initiated, with confidence in achieving MMR as a primary endpoint [22][23] Additional Insights - **Patient Population**: - High baseline disease burden among trial participants, with 64% showing lack of efficacy to previous treatments [12][13] - Notable patient cases demonstrate Terns 701's effectiveness in individuals resistant to Asiminib [18][19] - **Future Directions**: - Terns plans to open a mutation cohort for patients with specific mutations, enhancing the understanding of Terns 701's efficacy [21] - Additional data releases and longer-term safety studies are anticipated in 2026 [26][27] Conclusion - Terns Pharmaceuticals is positioned to make significant advancements in CML treatment with Terns 701, backed by strong efficacy and safety data, a solid financial foundation, and strategic regulatory plans for 2026 [27]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned to profit from the surge in electricity demand driven by AI data centers [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It has a unique footprint in nuclear energy, which is considered vital for America's future power strategy [7][14] Financial Health - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines without the associated premium costs [9][10] Market Sentiment - There is a growing interest from Wall Street in this company, as it is seen as undervalued and capable of delivering real cash flows while owning critical infrastructure [8][10] - The company is trading at less than 7 times earnings, making it an attractive investment opportunity in the context of AI and energy [10][11] Future Outlook - The influx of talent into the AI sector is expected to drive rapid advancements and innovation, reinforcing the notion that investing in AI is backing the future [12][13] - The combination of AI infrastructure needs, energy demands, and the onshoring boom presents a unique investment landscape that this company is well-positioned to navigate [14][15]

Financial Position - Terns Pharmaceuticals has approximately $1.0 billion in cash, cash equivalents, and marketable securities as of year-end 2025, expected to provide a runway into 2031[1]. - Terns completed a public offering of 18,687,500 shares, generating gross proceeds of approximately $747.5 million before expenses[7]. Clinical Trials and Drug Development - The CARDINAL Phase 1/2 trial of TERN-701 is enrolling well, with over 85 patients enrolled as of December 8, 2025[7]. - TERN-701 achieved a major molecular response (MMR) rate of 75% (18/24) by 24 weeks in evaluable patients at the recommended phase 2 dose range of >320mg QD, significantly higher than asciminib[7]. - The company plans to select a pivotal dose for TERN-701 in mid-2026 and initiate a pivotal trial in late 2026 or early 2027[3]. - TERN-701 has been granted U.S. FDA Fast Track designation for the treatment of chronic myeloid leukemia (CML) in Q4 2025[1]. - The company aims to generate data that strengthens TERN-701's position as a potential best-in-disease therapy across all lines of CML treatment[2]. - The majority of treatment-emergent adverse events (TEAEs) in the CARDINAL trial were low grade, with no dose-limiting toxicities observed[3]. - Updated and expanded CARDINAL data is expected to be released in the second half of 2026[3]. Strategic Partnerships - The company is seeking a strategic partner to advance the TERN-501 and TERN-801 legacy metabolic programs[7].

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential to become the best-in-class therapy versus other existing treatments. At the 67th American Society of Hematology (ASH) Annual Meeting and Exposition early last mon ...

Group 1: Palvella Therapeutics Inc. (PVLA) - Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with no FDA-approved treatments [2] - Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and has a multi-billion-dollar market opportunity if approved [2] - The stock rose from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, before pulling back to $99.88 [3] Group 2: Cidara Therapeutics Inc. (CDTX) - Cidara is developing a preventive therapy for influenza and has agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion [4] - The stock was trading at $18.98 when profiled on November 21, 2024 [4] Group 3: Celcuity Inc. (CELC) - Celcuity is focused on targeted therapies for oncology, with its lead drug candidate Gedatolisib aimed at breast and prostate cancers [5] - The stock increased from $12.60 on December 4, 2024, to an all-time high of $112.64 on December 12, 2025, before retreating to $99.16 [6] Group 4: Nanobiotix (NBTX) - Nanobiotix is a late-stage clinical biotechnology company developing physics-based therapies for cancer [7] - Its lead candidate, NBTXR3, is undergoing a phase III study for head and neck squamous cell carcinoma, with interim data expected in the first half of 2027 [8] - The stock rose from $12.23 on September 19, 2025, to a high of $30.35 on October 13, 2025, before trading around $21 [10] Group 5: Terns Pharmaceuticals Inc. (TERN) - Terns Pharma is developing small-molecule candidates for serious diseases, with TERN-701 targeting chronic myeloid leukemia [12] - Recent data showed a 75% major molecular response rate among patients receiving higher doses [13] - The stock increased from $5.98 on August 6, 2025, to an all-time high of $48.26 on December 10, 2025, before pulling back to around $40 [14] Group 6: DBV Technologies S.A. (DBVT) - DBV Technologies is developing an epicutaneous immunotherapy for food allergies, with its lead product, the VIASKIN Peanut patch, showing positive results in a phase 3 study [15] - The company aims to submit a Biologics License Application in the first half of 2026, with potential sales of $1.5 billion by 2030 if approved [15] - The stock rose from $10.64 on October 2, 2025, to a high of $26.18 on December 17, 2025, before trading around $19 [16] Group 7: Nutex Health Inc. (NUTX) - Nutex Health reported a significant turnaround from a $424 million net loss in 2022 to a $59 million net income for the nine months ended September 30, 2025 [17] - Revenue increased from $219 million in 2022 to $723.6 million in the first nine months of 2025 [17] - The stock rose from $33.56 on November 25, 2024, to a 52-week high of $193.07 before closing at $182.23 [18] Group 8: Inhibrx Biosciences Inc. (INBX) - Inhibrx is developing biologic therapies for cancer, with Ozekibart showing significant improvement in progression-free survival in chondrosarcoma [19] - The company plans to submit a biologics license application for Ozekibart in the second quarter of 2026 [20] - The stock rose from $18.35 on July 8, 2025, to an all-time high of $94.57 on December 22, 2025, before trading around $77 [21] Group 9: GRAIL Inc. (GRAL) - GRAIL focuses on early cancer detection with its Galleri test, which is not yet FDA-approved [23] - The company expects to submit a PMA for the Galleri test in Q1 2026 [23] - The stock increased from $48.50 on September 26, 2025, to a high of $115.76 on November 25, 2025, before trading around $88 [24] Group 10: Cogent Biosciences Inc. (COGT) - Cogent is developing precision therapies for genetically defined diseases, with Bezuclastinib being its lead candidate [25] - The company submitted its first NDA to the FDA for Non-AdvSM, with additional submissions planned for GIST and advanced systemic mastocytosis [26] - The stock rose from $7.25 on July 2, 2025, to a 52-week high of $43.73 on December 8, 2025, before easing back to around $35 [26] Group 11: Sol-Gel Technologies Ltd. (SLGL) - Sol-Gel has two FDA-approved products for dermatological conditions and is developing investigational products [27] - A phase III trial for SGT-610 is ongoing, with results expected in Q4 2026 [28] - The stock rose from $7.26 on May 7, 2025, to a high of $52.26 on October 6, 2025, before trading around $43 [28] Group 12: Zenas BioPharma Inc. (ZBIO) - Zenas is focused on therapies for autoimmune diseases, with Obexelimab in phase 3 trials for IgG4-RD [29] - Positive data from a phase 2 trial in multiple sclerosis showed a 95% reduction in new lesions [30] - The stock rose from $8.79 on December 17, 2024, to a high of $44.60 on December 24, 2025, before pulling back to around $35 [31]

Company Overview - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) specializes in developing small-molecule therapies for cancer and obesity, with key products including TERN-701 for chronic myeloid leukemia, TERN-501 for metabolic liver disease, and oral obesity treatments through TERN-601 and TERN-800 programs [2]. Recent Developments - On December 8, Terns Pharmaceuticals announced positive results for TERN-701, reporting a 64% major molecular response (MMR) rate in Phase 1 trials [2]. - The therapy achieved a 75% response rate at doses of 320 mg and above over a 24-week period, supporting these doses as the recommended Phase 2 doses [2]. - The Chief Medical Officer, Emil Kuriakose, highlighted a 36% durable molecular response (DMR) achievement rate by 24 weeks, indicating fast response kinetics and a favorable safety profile across all doses [2]. Market Performance - The stock of Terns Pharmaceuticals experienced significant volatility, rising from approximately $2 to around $48 before a slight pullback, indicating strong market interest and potential investor excitement [1].